No Detail Found!

Is there an association between IDH1 Mutation, MGMTpromoterMethylation and Neurotrophic Kinase receptor expression in the development and progression of CNS tumours?

Author(s)
Fawaz Mohamed Department of Pathology, Faculty of Medicine, King Abdulaziz University,Rabigh,Saudi Arabia
Riffat Mehboob Research unit, Faculty of Allied Health Sciences, Lahore Medical Research Center, LLP,Lahore,Pakistan
Hanadi Talal Ahmedah Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University,Rabigh,Saudi Arabia
Imad Fadl-Elmula Department of Clinical Genetics, Faculty of Medicine, Al-Neelain University,Khartoum,Sudan
Ahmad Taher Alsaqafi Department of Anesthesia, King Abdullah medical complex, Jeddah, Kingdom of Saudia Arabia,,
Abstract
IDH mutation, MGMT methylation and Neurotrophic Tyrosine Receptor Kinase (NTRK) rearrangement have all been detected in different types of CNS tumours. The Pan-Trk protein plays an important role in the neuronal development and cellular growth. Our aim was to explore if Pan-Trk expression in tumour microenvironment is related to IDH mutation and MGMT methylation. This study included twenty-three patients diagnosed with different types of CNS tumours. Testing for Pan-Trk and IDH1 was performed on all FFPE tissues. This assessment has been correlated with MGMT methylation and NTRK rearrangement. The mean age of all cases was 36 years; 19 tumours were glial, and the remaining 4 cases were non-glial. IDH-mutation was identified in 5 tumours (21.7%) and the remaining cases were IDH-wildtype (78.3%). MGMTpromoter was methylated in 4 cases (17.4%) and 19 cases (91.3%) showed unmethylated MGMT. Pan-Trk was expressed in 11 tumours (47.8%) and the rest (52.2%) showed no Pan-Trk expression. There was no statistically significant association between Pan-Trk expression, IDH-mutation and MGMT methylation (p>0.05). There was also no statistically significant relationship between these three biomarkers with recurrence-free interval (RFI). The late recurrence was only observed among tumours having expressed PanTrk, IDH-mutation and unmethylated MGMT (Median =20.32 months). About 60% of cases who received chemotherapy have showed longer RFI however, no significant association was observed (p= 0.567). Pan-Trk should not be used as a screener to detect NTRKrearrangement in CNS tumours but can be considered as a signalling biomarker to understand the relationship between IDH-mutation and MGMT-promoter methylation in tumours microenvironment.
Publication Details
Page(s) 1498-1503
DOI DOI not available
Published Journal: Bioscience Research, Volume: 19, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
IDH mutation, CNS tumours, MGMT-promoter methylation, Pan-Trk
0

Citations

0

Downloads

43

Views